Announced Wed, 29 Jul · 21:01 IST
Piramal Pharma Q1 FY27: Revenue up 17%, EBITDA margin expands to 12.5%
Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDFExplain this filing
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.2%1-day move
₹195.20
prior close
₹194.99
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.8+1.3+1.0+1.6-0.2+2.3+3.4+5.0+6.5+9.8+11.0———
Up moveDown movePending
AI summary
Piramal Pharma Q1 FY27 revenue rose 17% YoY to Rs 2,270 Cr. All three businesses grew: CDMO 19%, CHG 17%, PCH 15%. EBITDA surged 72% to Rs 285 Cr, with margin expanding 400 bps to 12.5%. Net loss narrowed to Rs 69 Cr from Rs 102 Cr. Management guided for sustained revenue growth and EBITDA expansion through FY27. US FDA issued EIR for Sellersville facility. Kenalog supplies to begin Q2FY27.
Likely market impact
Strong start to FY27 with broad-based growth and sharp margin expansion signals turnaround; sustained profitability improvement is the key watchpoint.